| The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders K Socała, U Doboszewska, A Szopa, A Serefko, M Włodarczyk, ... Pharmacological research 172, 105840, 2021 | 453 | 2021 |
| The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases A Piechota-Polanczyk, J Fichna Naunyn-Schmiedeberg's archives of pharmacology 387, 605-620, 2014 | 400 | 2014 |
| Opioid receptors and their ligands A Janecka, J Fichna, T Janecki Current topics in medicinal chemistry 4 (1), 1-17, 2004 | 370 | 2004 |
| The endomorphin system and its evolving neurophysiological role J Fichna, A Janecka, J Costentin, JC Do Rego Pharmacological reviews 59 (1), 88-123, 2007 | 358 | 2007 |
| Distribution, function and physiological role of melatonin in the lower gut CQ Chen, J Fichna, M Bashashati, YY Li, M Storr World journal of gastroenterology: WJG 17 (34), 3888, 2011 | 307 | 2011 |
| Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives M Sobczak, M Sałaga, MA Storr, J Fichna Journal of gastroenterology 49, 24-45, 2014 | 253 | 2014 |
| Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease A Wasilewski, M Zielińska, M Storr, J Fichna Inflammatory bowel diseases 21 (7), 1674-1682, 2015 | 226 | 2015 |
| Synthesis of target-specific radiolabeled peptides for diagnostic imaging J Fichna, A Janecka Bioconjugate chemistry 14 (1), 3-17, 2003 | 225 | 2003 |
| Brain-gut interactions in IBS J Fichna, MA Storr Frontiers in pharmacology 3, 127, 2012 | 188 | 2012 |
| The role of morphine in regulation of cancer cell growth K Gach, A Wyrębska, J Fichna, A Janecka Naunyn-Schmiedeberg's archives of pharmacology 384, 221-230, 2011 | 180 | 2011 |
| Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential A Janecka, A Wyrębska, K Gach, J Fichna, T Janecki Drug Discovery Today 17 (11-12), 561-572, 2012 | 173 | 2012 |
| LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity A Fabisiak, N Murawska, J Fichna Pharmacological Reports 68 (4), 802-808, 2016 | 166 | 2016 |
| Effects of berberine in the gastrointestinal tract—a review of actions and therapeutic implications C Chen, Z Yu, Y Li, J Fichna, M Storr The American journal of Chinese medicine 42 (05), 1053-1070, 2014 | 142 | 2014 |
| A randomized clinical trial of berberine hydrochloride in patients with diarrhea‐predominant irritable bowel syndrome C Chen, C Tao, Z Liu, M Lu, Q Pan, L Zheng, Q Li, Z Song, J Fichna Phytotherapy Research 29 (11), 1822-1827, 2015 | 140 | 2015 |
| Polyphenols as mitochondria-targeted anticancer drugs S Gorlach, J Fichna, U Lewandowska Cancer Letters 366 (2), 141-149, 2015 | 134 | 2015 |
| Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review M Sałaga, H Zatorski, M Sobczak, C Chen, J Fichna Current treatment options in oncology 15, 405-420, 2014 | 126 | 2014 |
| Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases M Sobczak, A Fabisiak, N Murawska, E Wesołowska, P Wierzbicka, ... Pharmacological Reports 66 (5), 766-775, 2014 | 119 | 2014 |
| The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases M Piotrowska, M Swierczynski, J Fichna, A Piechota-Polanczyk Pharmacological Research 163, 105243, 2021 | 116 | 2021 |
| Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment N Murawska, A Fabisiak, J Fichna Inflammatory bowel diseases 22 (5), 1198-1208, 2016 | 111 | 2016 |
| Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH) M Sałaga, A Mokrowiecka, PK Zakrzewski, A Cygankiewicz, E Leishman, ... Journal of Crohn's and Colitis 8 (9), 998-1009, 2014 | 108 | 2014 |
